Introduction
The major histocompatibility complex (MHC) plays a pivotal role in adaptive immune responses by presenting peptides on antigen presenting cell surfaces for subsequent T cell recognition (Goulder and Walker, 2012; Koch et al., 2007; Liu et al., 2011c) . For the human MHC, human leukocyte antigen (HLA) alleles possess an extremely high amount of polymorphisms (de Bakker et al., 2006; Marsh et al., 2010) . Initially, the HLAs were classified into different serotypes according to their antigenicities (Marsh et al., 2010) . Recently, with the identification of numerous peptides that bind to different HLA proteins, the peptide presentation characteristics of HLAs have given rise to a new categorization. HLA molecules with similar peptide binding features are grouped into the same supertypes (Lund et al., 2004; Naugler and Liwski, 2008; Sette et al., 2003; Sidney et al., 1996) . Nine major supertypes of HLA class I (HLA I) proteins have been defined based on their shared overlapping peptide-presentation repertoires in the same supertype (Doytchinova et al., 2004a; Reche and Reinherz, 2007; Sidney, 1998, 1999b; Sidney et al., 2008) . Each supertype possesses similar peptide binding motifs.
A2 and A3 are two supertypes with relatively higher frequencies of occurrence (in the range of 39-46% for A2 and 37-53% for A3) among major ethnic groups worldwide compared to other supertypes (del Guercio et al., 1995; Longmate et al., 2001; Zhu et al., 2006) . The A2 supertype includes HLA-A*0201 to HLA-A*0207, HLA-A*6802, and HLA-A*6901, etc. These alleles are characterized by a peptide motif of small or aliphatic hydrophobic residues (e.g., Ala, Leu, Ile, Val, Met, Ser, or Thr) at both position 2 and the C-terminal position (Barouch et al., 1995; del Guercio et al., 1995; Doytchinova and Flower, 2002; Fogg et al., 2009; Liu et al., 2010a; Sidney et al., 2001) . To date, although most of the defined immunogenic peptide epitopes are with the HLA-A*0201-restriction, dozens of cross-allele-presented peptides have been identified within the A2 supertype (del Guercio et al., 1995; Fogg et al., 2009; Mitchell et al., 2000) . The A3 supertype mostly comprises HLA-A*0301, HLA-A*1101, HLA-A*3101, HLA-A*3301, and HLA-A*6801, etc., which present peptides with similar features such as preferences for small or aliphatic residues (e.g., Ala, Leu, Ile, Val, Met, Ser, or Thr) at position 2 and positively charged residues (Arg or Lys) at the C-terminus of the peptides (Doytchinova et al., 2004b; Guan et al., 2003; Hattotuwagama et al., 2007; Sidney et al., 1996) .
Interestingly, two relatively common HLA types, HLA-A*6802 and HLA-A*6801, possess only five polymorphic amino acids and belong to the same serotype HLA-A68 (Fernandez-Vina et al., 1992; Marsh et al., 2010) . Three of the five polymorphic amino acids locate in the F pocket of the peptide binding groove, while the other two locate in the positions which have no direct effect on peptide binding or T cell recognition (based on the previous TCR-MHC complexes). However, based on their distinct peptide binding properties, HLA-A*6802 and HLA-A*6801 can definitively be grouped into the A2 and A3 supertypes, respectively (Sidney et al., 2008) . Elucidation of the molecular basis of the divergent peptide presentation characteristics of HLA-A*6802 and HLA-A*6801, which determine their different HLA supertype classification, requires detailed structural exploration (Gostick et al., 2007) . Furthermore, different disease correlation of HLA-A*6802 and HLA-A*6801 was reported (Conway et al., 1997 (Conway et al., , 1996 . It is indicated that HLA-A*6802 allele within the A2 supertype is associated with reduced risk of HIV-1 infection and transmission (MacDonald et al., 2001a (MacDonald et al., , 2000 (MacDonald et al., , 2001b Rowland-Jones et al., 1998) . The particularly efficient HIV-specific CTL responses or present epitopes restricted by particular MHC alleles such as HLA-A*6802 may act as one of the restricting elements (Chen et al., 2012; Walker and McMichael, 2011; Wu et al., 2011) . However, the association of HLA-A*6801 and HIV infection still remain in debate although it is reported that the HLA-A68 serotype is associated with higher viral load in HIV (Gostick et al., 2007; Ngandu et al., 2009; Tang et al., 2002) . Therefore, it is indispensable to characterize the peptide presentation of HLA-A*6802 and perform a comparative analysis with its related allele HLA-A*6801 and HLA-A*0201.
In our previous study, we illuminated the structural basis of cross-allele presentation by HLA-A*0301 and HLA-A*1101 by characterizing their structures complexed to peptide RT313 . In this study, we determined the crystal structures of both HLA-A*6802 and HLA-A*6801 complexed with their typically presented peptides, respectively, two of which are HIV-specific antigenic peptides (Env199 and RT313). The structure of HLA-A*6802 complexed with self peptide TRP2-180 derived from a tumor antigen TRP2 was also determined. The binding capabilities of the peptides to HLA-A*6802 and HLA-A*6801, together with HLA-A*0201, were characterized. Our results provide a molecular basis for the supertype differentiation between HLA-A*6801 and HLA-A*6802 and offer a structural reference for understanding HIV-specific T cell immunity among populations with different HLA supertypes (Lichterfeld et al., 2006; Ojesina et al., 2006) .
Materials and methods

Peptide synthesis and preparation of the HLA complexes by in vitro refolding
The nonamer peptides Env199 (TLTSCNTSV) derived from human immunodeficiency virus (HIV) Envelope protein (199) (200) (201) (202) (203) (204) (205) (206) (207) , RT313 (AIFQSSMTK) of HIV reverse transcriptase (313-321), and a human self peptide TRP2-180 (SVYDFFVWL) from Tyrosinaserelated protein 2 (180-188) were synthesized Li and Bouvier, 2004; Madden et al., 1993; Parkhurst et al., 1998; Threlkeld et al., 1997; Zhang et al., 2011) , and their purity was determined as ∼95% by analytical high-performance liquid chromatography (HPLC) and mass spectrometry (Scilight-Peptide, Inc.). The peptides were stored at −80 • C as freeze-dried powders and were dissolved in dimethyl sulfoxide (DMSO) before use. The cDNA of HLA-A*6802 (residues 1-274) was obtained through overlap extension PCR utilizing HLA-A*6801 as a template, which was previously constructed in our laboratory (Gao et al., 2000) . The HLA complexes were prepared using in vitro refolding as previously described (Garboczi et al., 1992; Li et al., 2011; Liu et al., 2011b) . Briefly, the HLA heavy chain and human ␤ 2 m were expressed in inclusion bodies containing in Escherichia coli and co-refolded with peptides in a 400 mM L-arginine refolding buffer. Subsequently, the HLA complexes were purified using Superdex ® 75 10/300 GL gel filtration chromatography and Resource-Q anion-exchange chromatography (GE Healthcare). Before crystallization, the final buffer was exchanged to 20 mM Tris-HCl (pH 8.0) and 50 mM NaCl.
Crystallization, data collection, and processing
Crystallization was performed using the hanging drop vapor diffusion technique. Plates were incubated at 291 K and checked for crystal growth one week later. HLA-A*6802/Env199 crystals grown in 0.1 M ammonium acetate, 0.1 M Bis-Tris (pH 6.5), and 17% (w/v) PEG 10,000 at 10 mg/mL. Crystals of HLA-A*6802/TRP2-180 were observed in 100 mM Tris (pH 8.5), and 8% PEG8000 at a protein concentration of 15 mg/mL. Single crystals of HLA-A*6801/RT313 were obtained in a 0.1 M HEPES (pH 7.0) and 30% (v/v) Jeffamine ED-2001 solution with a protein concentration of 10 mg/mL. Diffraction data for HLA-A*6802/Env199 and HLA-A*6802/TRP2-180 were collected at 100 K at the SSRF BEAMLINE BL17U, Shanghai, China at a wavelength of 0.9793Å. Diffraction data for HLA-A*6801/RT313 were collected using an in-house X-ray source (Rigaku MicroMax007 desktop rotating anode X-ray generator with a Cu target operated at 40 kV and 30 mA) and an R-Axis IV++ imaging-plate detector at a wavelength of 1.5418Å. In each case, the crystal was first soaked in reservoir solution containing 15% glycerol as a cryoprotectant for several seconds and then flash-cooled in a stream of gaseous nitrogen at 100 K. The collected intensities were subsequently processed and scaled using the DENZO program and the HKL2000 software package (HKL Research).
Structure determination and refinement
The HLA-A*6801/RT313 structure was solved by the molecular replacement method using HLA-A*0301 (Protein Data Bank [PDB] code 3RL1) as the search model in the Crystallography and NMR System (CNS) program (Brunger et al., 1998) . The different residues between HLA-A*6801 and the search model HLA-A*0301 were manually rebuilt in the program COOT (Emsley and Cowtan, 2004) . Subsequently, restrained refinement was performed using REFMAC5 (Murshudov et al., 1997) . Further refinement was performed using the PHENIX software package with isotropic ADP refinement and bulk solvent modeling (Adams et al., 2010) . The stereochemical quality of the final model was assessed with PROCHECK (Laskowski et al., 1993) . The model of HLA-A*6801/RT313 was subsequently used to determine the structure of HLA-A*6802/Env199 and HLA-A*6802/TRP2-180 by molecular replacement. Crystallographic statistics for the final models of the two complexes are given in Table 1 . Figures were generated using PyMOL (http://www.pymol.org/).
Accession numbers
The accession numbers of HLA-A*6802/Env199, HLA-A*6802/TRP2-180 and HLA-A*6801/RT313 in PDB are 4I48 (http://www.pdb.org/pdb/search/structidSearch.do?structureId= 4I48), 4HX1 (http://www.pdb.org/pdb/search/structidSearch. 
Results
Overall structures of HLA-A*6802 and HLA-A*6801
The structures of HLA-A*6802 complexed with two peptides Env199 and TRP2-180 were determined to resolutions of 2.8 and 1.8Å, respectively and the HLA-A*6801/RT313 structure is constructed at a resolution of 2.4Å (Table 1) . As expected, the overall structures of HLA-A*6802 and HLA-A*6801 display the common characteristics of other structurally determined HLA I proteins including the previously determined HLA-A*6801 and HLA-A*0201 structures ( Fig. 1A -C) (Bjorkman et al., 1987; Guo et al., 1992 Guo et al., , 1993 . The extracellular region of HLA-A*6802 heavy chain folds into three different domains: a typical MHC molecule superfamily domain formed by the ␣1 and ␣2 domains, and an immunoglobulin like ␣3 domain which underpins the ␣1 and ␣2 domains together with ␤-microglobulin. The peptides lie along the peptide binding groove formed by two ␣-helices and eight ␤-sheets within the ␣1 and ␣2 domains.
The overall structure of HLA-A*6802 is extremely similar to that of HLA-A*6801, with a root mean square deviation (RMSD) of 0.784Å when the whole molecule of HLA-A*6801/RT313 was superimposed with HLA-A*6802/Env199 (Fig. 1D up left and down left). However, the superposition of the structure of HLA-A*6802/Env199 with the previously determined HLA-A*6802/Env199 structure generated an RMSD of 1.536Å (Fig. 1D up right and up down) . This is concordant with the higher identity of the amino acid sequences of HLA-A*6802 aligned to HLA-A*6801 (98.2%) than the identity between HLA-A*6802 and HLA-A*0201 (95.6%) ( Fig. 2A ). Crystal packing of the molecules within these structures has not direct interactions through the HLA helices and thus does not affect the overall structures. The structural alignments of the HLA-A*6801 and HLA-A*6802 with the previously determined HLA-A*6801 and HLA-A*0201 structures also illuminate the similar overall structures of HLA-A*6802 and HLA-A*6801 but not HLA-A*0201. This may indicate a comparable antigenicity between HLA-A*6802 and HLA-A*6801, which gives rise to the similar serotype classification of these two alleles. Furthermore, there are six polymorphic residues between HLA-A*0201 and HLA-A*6801, and HLA-A*6802 that are exposed to the solvent (Supplemental Fig.  1 ). The solvent-exposed amino acid may locate in the serological recognition of the HLA molecules. Four out of the six polymorphic residues are conserved between HLA-A*6801 and HLA-A*6802, but different from HLA-A*0201, which may contribute to the different serological typing of HLA-A*6801/6802 and HLA-A*0201. HLA-A*6801 has been indicated to be a weak binder for CD8␣␣ due to a polymorphic residue V245, which has previously been observed to change the conformation of the 223-229 loop region in ␣3 domain. This conformation shift of the 223-229 loop is also observed in HLA-A*6802 structure compared to HLA-A*0201 which may indicate a weak CD8␣␣ binding for HLA-A*6802.
The electron densities for the three bound peptides are welldefined inside the peptide binding grooves of HLA-A*6802 and HLA-A*6801, respectively ( Fig. 1A-C ). All the peptides utilize residues in position 2 (P2) from the N-terminus and residues at their C-terminus (Pc) as the primary anchors with similar conformations (Leu for Env199, Val for TRP2-180 and Ile for RT313 at P2; Val for Env199, Leu for TRP2-180 and Lys for RT313 at Pc). The crystal packing of the molecules from different asymmetric units of the HLA-A*6802 and HLA-A*6801 structures showed that the adjacent packed molecules have no contact with the peptides, which may indicate the structures determined herein display a natural peptide presentation.
3.2. The peptide presentation of HLA-A*6802 is similar to HLA-A*6801 but not HLA-A*0201
The structure of peptide Env199 complexed with HLA-A*0201 has been determined previously , which make it possible to compare the peptide presentation of HLA-A*6802 
Thr73 and HLA-A*0201 using the similar peptide ( Table 2 ). The main chain conformation of the peptides presented by HLA-A*6802 and HLA-A*0201, together with HLA-A*6801 are similar. However, the residues in the middle portion of the peptide Env199 presented by HLA-A*6802, is different from the Env199 presented by HLA-A*0201 (Fig. 3A) . The HLA-A*0201-presented peptide Env199 adopts a bulged conformation, with the P6 residue Asn pointing out of the groove. In contrast, the peptide Env199 in the HLA-A*6802 groove presents a flat conformation, with the P6 residue Asn protruding toward the ␣1-helix.
Due to the different peptide motif preference, we failed in the refolding the HLA-A*6802 and HLA-A*6801 with the same peptides. We determined the structures of HLA-A*6802 and HLA-A*6801 with different peptides: Env199 and RT313, respectively. We found that the main chain conformation and the orientations of residue side chains are extremely similar between the two peptide presented by HLA-A*6802 and HLA-A*6801 ( Fig. 3B and C) . Both the P6 residues of the two peptides (Asn for Env199, Ser for RT313) point their side chains to the ␣1-helix (Fig. 3C) . The P6-Asn of Env199 and P6-Ser of RT313 form hydrogen bonds with the residues on the ␣1-helix, e.g. Gln70 and Thr73 which are conserved between HLA-A*6802 and HLA-A*6801 ( Figs. 2A and 3D ). This indicates a secondary anchor role for hydrophilic residues at the P6 position of the peptides presented by HLA-A*6802 and HLA-A*6801. However, for HLA-A*0201, the hydrophilic residue P6-Asn of Env199 does not form any contact polymorphic residue His70 ( Fig. 2A ), but protrude upward ( Fig. 3C and D) , which is concordance with the previous conclusion that the HLA-A*0201 usually has a hydrophobic secondary anchor at P6 position to poke into the groove. The hydrophilic residue such as Asn will be repelled out of the hydrophobic C pocket of HLA-A*0201.
3.3. F pockets with distinct static electrical statuses govern the divergent peptide binding motifs of HLA-A*6802 and HLA-A*6801
Previous studies have elucidated that HLA-A*6802 prefers peptides with the typical HLA-A*0201-restricted peptide motif that is different from the one of HLA-A*6801 (Barouch et al., 1995; del Guercio et al., 1995) . Herein, we utilized an in vitro refolding assay to analyze the binding capabilities of HIV peptides Env199 and RT313 to HLA-A*6802, HLA-A*6801, and HLA-A*0201. The typical A2 supertype peptide Env199 facilitated the renaturation of both HLA-A*6802 and HLA-A*0201 but not HLA-A*6801 into soluble complexes reflected by the lack of refolded protein. In contrast, RT313 with its classical A3 supertype peptide motif assisted the refolding of HLA-A*6801 but displayed no binding to either HLA-A*6802 or HLA-A*0201 ( Fig. 4A and B) .
Peptides Env199 and RT313 have similar aliphatic P2 anchors (Leu in Env199 and Ile in RT313) but differently-charged Pc anchors (Val in Env199 and Lys in RT313). This implies that the F pockets of the three HLA alleles HLA-A*6802, HLA-A*6801, and HLA-A*0201, which accommodate the Pc anchor residues, may contribute to their different binding affinities for the TRP2-180 and RT313 peptides. Structural analysis indicated that the static electrical statuses of the HLA-A*6802 and HLA-A*0201 F pockets are quite different from HLA-A*6801 ( Fig. 4C-E) . HLA-A*6802 and HLA-A*0201 bear highly hydrophobic F pockets, while HLA-A*6801 possesses a negatively charged F pocket. The F pockets The key polymorphic residues within the F pockets of HLA-A*6802 and HLA-A*6801 are marked with green asterisks. The key polymorphic residues within the B/C pockets of HLA-A*6802 and HLA-A*0201 are marked with blue asterisk. The sequence alignment was generated with Clustal X and ESPript. (B) Two groups of A2 supertype alleles based on the match of structurally-determined key residues conferring HLA-A*0201-like and HLA-A*6802-like polymorphisms. The representative F pocket residues (green) Arg97, His114, and Tyr116 as in (A) retain the same in all the A2 supertype alleles. In contract, in the B/C pockets, the A2 supertype alleles from "Group 1" have residues Glu63, Lys66, and His70, while the "Group 2" alleles possess Gln63, Gln66 and Asn70, with only His70 of HLA-A*6815 and HLA-A*6831 as exception. #: HLA-A*6815, HLA-A*6827, HLA-A*6828, and HLA-A*6901 are defined into the A2 supertype previously based on the previous experimental or bioinformatic studies. Other alleles are listed in A2 supertype herein according to the prediction based on the key residues in F pocket determined in our structures. of HLA-A*6802 and HLA-A*0201 are formed by nearly identical residues, which include the similar hydrophobic residue Tyr116 located exactly at the bottom of the F pocket (Fig. 4F) . However, the residues composing the F pocket of HLA-A*6801 are quite different, characterized by a negatively charged Asp116 forming a tight salt bridge with the Pc anchor Lys of RT313 (Fig. 4G) . Although there are only five polymorphic residues between HLA-A*6802 and HLA-A*6801 (Arnett and Parham, 1995) , three of them are located in the F pocket, which leads to a divergent peptide selection of these two closely related HLA alleles within the same serotype.
B pockets of HLA-A*6802 and HLA-A*6801 subtly differed to HLA-A*0201
Previous studies indicated that the peptides presented by A2 and A3 HLA alleles have the small and aliphatic residues (Ala, Ser, Thr, Val, Leu, Ile, Met) for the P2 primary anchor in the B pocket of the peptide binding groove (Sette and Sidney, 1999a; Sidney et al., 2008) . The three peptides we studied here possess the typical residues (Val, Leu, and Ile) for the P2 anchor. This identical P2 anchor preference of HLA-A*6802, HLA-A*6801, and HLA-A*0201 imply a largely similar B pocket formation of the three alleles. Based Superimposition of HLA-A*6802-presented peptide Env199 (purple) with RT313 (cyan) from the HLA-A*6801 structure. Similar main chain conformation and the side chain orientation of the residues within these two peptides are observed. (C) Side chain orientation for the the peptides presented by HLA-A*6802, HLA-A*6801 and HLA-A*0201 as viewed in profile from the peptide N-terminus toward the C-terminus (up is toward the T cell receptor, down is toward the floor of the peptide binding groove, left is toward the ␣1 helix domain, and right is toward the ␣2 helix domain). The residues at position 6 of the peptides with different orientations between HLA-A*6802 and HLA-A*0201 are marked with red rectangle. (F) The magnified view of the residues in the middle part of the peptides presented by HLA-A*6802, HLA-A*6801 and HLA-A*0201. Asn6 of peptide Env199 in HLA-A*6802/Env199 and Ser6 in peptide RT313 in HLA-A*6801/RT313 bind to the residues Gln70 and Thr73 through hydrogen bonds. No direct interact is observed between Asn6 of Env199 in HLA-A*0201/Env199 with the residues on the ␣1 helix of HLA-A2. on our structures of HLA-A*6802, HLA-A*6801 and the previous determined HLA-A*0201/Env199, comparative analysis indicated that the similar hydrophobic residues Tyr7, Tyr9 (Phe9 for HLA-A*0201), Ala24, Val34, Val67 form the bottom of the B pocket of HLA-A*6802, HLA-A*6801, and HLA-A*0201 which adopt the side chain of the P2 anchor ( Fig. 5A-C) . However, the HLA-A*0201 has a small B pocket entrance compared to HLA-A*6802 and HLA-A*6801. A salt bridge at the edge of B pocket of HLA-A*0201 was observed between the two polymorphic residues Glu63 and Lys66 for HLA-A*0201 (Fig. 5D ). Although the polymorphism of the residues at these two positions may not impact the P2 anchor selection of HLA-A*6802, HLA-A*6801, and HLA-A*0201, the exposing of the two residues to solvent may influences the TCR-docking at this region of the MHC. This may contribute to the distinct MHC-restricted TCR recognition of HLA-A*6802/HLA-A*6801, compared to HLA-A*0201. Actually, the polymorphic residues at position 63 between HLA-A*6802 and HLA-A*0201 also contribute to the different conformation of the P1 anchoring of peptide Env199 in the two related structures (Fig. 5D ). In the structure of HLA-A*0201/Env199, a hydrogen bond is formed between Glu63 of heavy chain and P1 anchor Thr of Env199. However, no hydrogen bond is observed between Gln63 and P1 anchor Thr of Env199 in the structure of HLA-A*6802/Env199 (Table 2) . This also indicates a subtle impact of the micropolymorpism between HLA-A*6802/HLA-A*6801 and HLA-A*0201 on their peptide presentation and T cell recognition.
Unconventional peptide presentation of HLA-A*6802 revealed by a distinct P3-Tyr anchoring of TRP2-180
In order to further demonstrate and confirm the peptide presentation strategies of HLA-A*6802, we determined another structure of HLA-A*6802 complexed with self peptide TRP2-180 derived from a tumor antigen TRP2. The overall structure of HLA-A*6802/TRP2-180 and the conformation of peptide TRP2-180 are similar to the one in structure of HLA-A*6802/Env199 with a RMSD of 0.583Å. However, when we compare the structures of HLA-A*6802/TRP2-180 with all the HLA-A*0201 structures available on the PDB, we found that Tyr3 of TRP2-180, which acts as a secondary anchor residue, uncommonly inserts its side chain into the C pocket of HLA-A*6802. Instead, D pocket of HLA-A*6802 accommodates Phe5 of peptide TRP2-180. In contrast, the D pocket of HLA-A*0201 accommodates the P3 residues in all of the HLA-A*0201-presented peptides to the best of our knowledge (Fig. 6A) .
Further structural analysis demonstrated that the Tyr3 of TRP2-180 forms a hydrogen bond with Gln70 of the ␣1-helix of HLA-A*6802, which corresponds to a polymorphic residue, His70, in HLA-A*0201 (Fig. 6B) . This illuminates the contribution of allele-specific micropolymorphisms to the unconventional P3 Tyr anchoring of HLA-A*6802 presented peptide. A previous study indicates that the peptides presented by the HLA alleles from the A2 supertype prefer aromatic amino acids such as Tyr as secondary anchors at the P3 position (Sidney et al., 2001) . Herein, base on the structure of HLA-A*6802/TRP2-180, a different binding mode for the P3 Tyr anchor of HLA-A*6802 is displayed when compared to other A2 supertype members (Liu et al., 2011a) . In accord with the unusual P3 Tyr anchoring, the middle portion of the peptide binding groove of HLA-A*6802/TRP2-180 is wider than HLA-A*0201 (Fig. 6C) , and a larger and deeper C pocket can be observed within the groove of HLA-A*6802 ( Fig. 6D and E) . This may be associated with the uncommon anchoring conformation of P3 Tyr which repels the underside and flank of C pocket of HLA-A*6802 peptide binding groove. Fig. 4 . The binding peptide motif of HLA-A*6802 is similar to HLA-A*0201 but not HLA-A*6801, determined by the properties of the F pockets. A and B. Binding of Env199 (A) and RT313 (B) to HLA-A*6802, HLA-A*6801, and HLA-A*0201 is elucidated by in vitro refolding. Peptides with the ability to bind to the HLA help the HLA heavy chain and ␤2m refold in vitro. After properly refolding, we found that high-absorbance peaks of the MHCs with the expected molecular mass of 45 kDa eluted at the estimated volume of 65 ml on a Superdex ® 75 10/300 GL column (GE Healthcare). The profile is marked with the approximate positions of the molecular mass standards of 75.0, 43.0, and 29.0 kDa. Complexes were formed by refolding of peptide Env199 with HLA-A*6802 and HLA-A*0201 but not with HLA-A*6801. On the contrary, peptide RT313 aided HLA-A*6801 renature into a soluble complex but displayed no binding to HLA-A*6802 or HLA-A*0201. C-E. Vacuum electrostatic surface potential shows that the F pockets of HLA-A*6802 (C) and HLA-A*0201 (D) are hydrophobic, which differs from the negatively charged F pocket of HLA-A*6801 (E). The Pc anchor residues are represented in sticks and balls with different colors (purple for HLA-A*6802-presented Env199, yellow for HLA-A*0201-presented Env199 in 1HHG, and cyan for HLA-A*6801-presented RT313). (F) Comparison of the F pocket residues of HLA-A*6802 and HLA-A*0201. The heavy chains are represented as gray loops. The major residues (purple sticks) of the F pocket of HLA-A*6802 have the same conformation as the corresponding residues (yellow sticks) of HLA-A*0201. The Pc residue Val of Env199 presented by HLA-A*6802 and HLA-A*0201, respectively, are shown in purple and yellow sticks and balls. (G) Distinct F pockets of HLA-A*6802 and HLA-A*6801. The residues of the HLA-A*6801 heavy chain are represented in cyan. The Pc Val of the HLA-A*6802-bound peptide Env199 and the Pc Lys of the HLA-A*6801-bound peptide RT313 are shown as purple and cyan sticks and balls, respectively. The salt bridge between the Pc Lys of RT313 and Asp116 of the HLA-A*6801 F pocket is represented as black dashed lines. In (F) and (G), the names of residues that are similar between HLA-A*6802 and HLA-A*0201 or between HLA-A*6802 and HLA-A*6801 are labeled in black; the different ones are labeled according to the colors of the residues.
Discussion
Our studies demonstrate that HLA-A*6802 possesses a similar overall structure to HLA-A*6801, indicating an identical serotype classification. However, the conformations of the polymorphic residues within the peptide binding groove of HLA-A*6802, especially the F pocket, are distinct from HLA-A*6801 but similar to HLA-A*0201. This determines the A2 supertype-like peptide binding motif of HLA-A*6802 as HLA-A*0201. Interestingly, the peptide presentation strategy of HLA-A*6802, e.g. the conformations of the N terminal and the middle portion of the peptide, are more homologous to HLA-A*6801 compared to HLA-A*0201. Therefore, our comparative structural analyses of HLA-A*6802 and HLA-A*6801 together with HLA-A*0201 indicate an unusual peptide presentation feature of HLA-A*6802 , which may imply a unique pathogen specific T cell recognition within HLA-A*6802 + populations (Hogan et al., 1998; Rowland-Jones et al., 1998) .
Previous experimental and bioinformatic studies have indicated that there are still many other HLA-A alleles (e.g. HLA-A*6815, The heavy chains are represented as gray loops. The major residues of the B pocket of the three alleles are in the same conformation. The polymorphic residues Glu63 and Lys66 of HLA-A*0201 form the salt bridge (black dashed lines) which is different from HLA-A*6802 and HLA-A*6801. The names of residues that are similar between HLA-A*6802, HLA-A*6801, and HLA-A*0201 are labeled in black; the different ones are labeled according to the colors of the residues. The position of the P2 anchors of the peptides presented by these three alleles are represented by the P2 Leu of HLA-A*6801/Env199 shown in purple sticks and spheres with surfaces.
HLA-A*6827, HLA-A*6828, and HLA-A*6901, etc.) within the A2 supertype (Sidney et al., 2008) , which present the typical A2 restricted peptides (or have the A2 supertype polymorphic residues) but belong to the HLA-A68 or HLA-A69 serotypes (both are the subtypes of the common African broad antigen serotype A28) ( Fig. 2B) (Fernandez-Vina et al., 1992; Hsu et al., 1999; Krausa et al., 1993) . Detailed sequence and structure analyses indicated that these alleles posses the A2 supertype specific residues (as Arg97, His114, and Tyr116) in F pocket, as HLA-A*6802 ( Fig. 2A) . However, within the B and C pockets, these HLA-A*6802-like alleles bear residues (e.g. Gln63, Gln66, and Asn70) which are distinct from typical A2 alleles (HLA-A2 serotype alleles, such as HLA-A*0201 to HLA-A*0207). The hybrid micropolymorphism of these HLA-A*6802-like alleles may lead to a featured peptide presentation characteristic as HLA-A*6802. Therefore, based on the structural properties of the micropolymorphism and potential different peptide presentations, the A2 supertype can be divided into two groups: Group1: HLA-A*0201-like (e.g. HLA-A*0201-0207, etc.) and Group2: HLA-A*6802-like alleles (e.g. HLA-A*6815, HLA-A*6827, HLA-A*6828, and HLA-A*6901, etc.). These two groups can present the peptides with similar motif at P2 and Pc positions but in subtle different conformations. A recent structural study elucidated the peptide presentation features of four HLA-A*0201-like molecules: HLA-A*0201, HLA-A*0203, HLA-A*0206, and HLA-A*0207 (Liu et al., 2011a) . Herein our structures of HLA-A*6802 provide the insights into the peptide presentation of the HLA-A*6802like group. Peptides with similar A2 supertype restricted motif can be presented by these two groups, but in different conformations. Furthermore, the TCR restriction may also differ between these two groups due to the polymorphic residues within the solventexposing region of ␣1 and ␣2 helixes. However, experimental exploration is needed to confirm the peptide binding and the TCR recognition features of A2 supertype alleles in a broader manner.
In spite of the micropolymorphism modulated different peptide presentations, many studies illuminated a common phenomenon of the cross-allele presentation of similar peptides by HLA-A*0201like and HLA-A*6802-like alleles. Mitchell et al. reported that within six naturally displayed HLA-A2.1-restricted melanoma specific CTL epitopes, four of the epitopes can also be recognized in the HLA-A*6802 context by the cross-reactive CTLs (Mitchell et al., 2000) . It is also indicated that HLA A2-restricted Epstein-Barr virus-specific CTLs were able to lyse EBV-infected B cells expressing different HLA A2 supertype alleles including A*0201, A*0202, A*0203, A*0204, A*0206, A*6802 and A*6901 (Khanna et al., 1998) . These findings indicated that although the peptide presentation of alleles (as HLA-A*0201 and HLA-A*6802) within the A2 supertype can (Liu et al., 2010b) . The existence of the two water molecules is clearly shown by electron density at the 1.0 contour level. (C) The peptide binding groove of HLA-A*6802 (green) is wider than HLA-A*0201 (yellow) at the middle portion where the C pocket is located. The distances are measured between the C␣ of Thr73 and Ala150 of the molecules HLA-A*6802/TRP2-180 and HLA-A*0201/Env199, respectively. (D and E) The surfaces of the peptide-binding grooves of HLA-A*6802 and HLA-A*0201 are shown in gray, and the peptides TRP2-180 and Env199 from the structures of HLA-A*6802 (D) and HLA-A*0201 (E) are represented as green or yellow stick models. The pink surface indicates a larger and deeper C pocket in HLA-A*6802 compared to HLA-A*0201. Pockets A to F are labeled in black letters. The C and D pockets of HLA-A*6802 accommodate the side chains of the P3 Tyr and P4 Phe of TRP2-180, respectively (D). The P3 Met of peptide Env199 points into the D pocket of HLA-A*0201 (E). be subtly modulated by the micropolymorphism, similar peptides can still be presented by these alleles and subsequently induce cross T cell responses in different HLA allele individuals. The existence of the cross-reactive CTLs can be comprehended through the recent concept of the promiscuity of CTL recognition established by the broadly structure determination of cross-reactive TCRs and the related MHC complexes (Borbulevych et al., 2009; Lichterfeld et al., 2006; Liu et al., 2012; Mongkolsapaya et al., 2006; Yin and Mariuzza, 2009 ). In addition, the similar processing and transportation of the antigenic peptides within the antigen presenting cells (APCs) within different HLA alleles is also a prerequisite for the peptide cross-allele presentation and recognition .
In previous study, we have identified a SARS coronavirusderived CD8 + T cell epitope N1 which is presented by HLA-A*2402 in an uncommon strategy (Liu et al., 2010b) . A dramatically similar overall conformation is observed between the two peptides presented by HLA-A*6802 and HLA-A*2402 (data not shown). Similar to our structure of HLA-A*6802/TRP2-180, the Lys3 residue of peptide N1 in the HLA-A*2402 structure also locates in the C pocket but not D pocket in the peptide binding groove. In HLA-A*6802/TRP2-180, Gln70 of the ␣1-helix of HLA-A*6802 grabs Tyr3 of peptide TRP2-180 through a hydrogen bond. Interestingly, for N1 presented by HLA-A*2402, intrachain hydrogen bonds between Lys3 and Gln5 is formed which stabilizes the main chain conformation of N1. Due to the hydrogen bonds contributed by the P3 anchor in C pocket, both of peptides TRP2-180 and N1 display a bulged conformation, in which the residues in the middle portion of the peptides protrude out of the peptide binding grooves. This bulged peptide conformation within HLA-A*6802/TRP2-180 and HLA-A*2402/N1 helps to expose the amino acids in middle region of the peptide for the TCR docking in T cell recognition.
The comparative structural characterization of peptide presentation of HLA-A*6802, HLA-A*6801, and HLA-A*0201 illuminates a molecular basis for their A2 and A3 supertype differentiation and demonstrates the rationality of the supertype classification of HLA alleles based on binding-peptide motif. Moreover, these findings also provide beneficial reference points for viruses and tumors specific T-cell recognition of broadly cross-allele presented peptide, but still delicately restricted by polymorphic HLA. Given the prevalence of the HLA-A68 + population in Africa and the close correlation of A2-A*6802 supertype in HIV resistance, our study may shed light on the T cell vaccine development of HIV.
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